The Periodic Table of Royalties

A structural classification of 64 pharmaceutical royalty instrument types
R⟨Base, Seniority, Term, Concentration, Stage⟩
Gross sales
Net sales
Profit share
Licensing income
Milestones
Tiered / blended
Synthetic
Structured / ABS
Hybrid instrument
Territorial / carved
Theoretical / emerging
11 500 RN1 Gold standard R⟨N,1,X,4,0⟩
11 = Complexity number (ZR) -- structural ordering index 500 = Market weight (W) -- typical deal size in $M RN1 = Symbol -- Group (N = net sales) + Period (1 = safe) Gold standard = Common name R⟨N,1,X,4,0⟩ = Structural formula (base, seniority, term, concentration, stage)
Observable ←—— economic base ——→ Engineered

Periodic properties

ZR
Complexity number
Composite score ordering all elements by base abstraction, structural layers, and model dependency. Like atomic number, it uniquely identifies each element and predicts behavior.
W
Market weight
Typical transaction size in $M. Analogous to atomic mass. Ranges from $5M (preclinical milestones) to $500M+ (RPFT portfolio acquisitions and senior ABS tranches).
V
Valence
Combinability into portfolio structures (0-4). V=4 elements like RN1 are ideal building blocks. V=0 elements like RS5 are inert: too unstable to form portfolio bonds.
Half-life
Median duration of cash flows. Patent-expiry royalties have predictable half-lives of 8-15 years. Synthetic structures may have unpredictable decay profiles.
Δ
Ionization energy
Difficulty of separating the royalty from its underlying asset for independent trading. Senior net sales royalties have low Δ. Embedded profit shares have very high Δ.

Capital for Cures AG · p05.org · Periodic Table of Royalties v3.0

Classification framework for analytical purposes. Not investment, legal, or financial advice.